CSI Market
Sign In | Register

Tarsus Pharmaceuticals Inc (TARS) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access TARS Annual Cash Flow →
Cash flow performance over multiple periods helps investors evaluate the stability of Tarsus Pharmaceuticals Inc's cash-generating activities.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-25.52
Depreciation & amortization0.96
Amortization of Other Assets0.81
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment-0.18
Share-based Compensation25.26
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), Unrealized0.01
Operating Lease Right Of Use Asset Amortization Expense-
Embedded Derivative Gain Loss On Embedded Derivative Net-
Gain Loss On Termination Of Lease-
Operating Lease Noncash Expense0.08
Income taxes0.00
Losses/ -gains on Investments net2.81
Accounts Receivable28.70
Accounts Payable0.00
Increase (Decrease) in Other Accrued Liabilities28.75
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense-3.86
Other Working Capital-0.20
Other Noncash Income (Expense)0.00
Other net-3.69
Payments for (Proceeds from) Other Operating Activities-17.27
Discontinued operations0.00
Net Cash flow from Operating Activities36.57
Investing Activities
Capital Expenditures-9.89
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities118.40
Payments to Acquire Available-for-sale Securities, Debt-129.20
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Long-term Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-20.68
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock4.51
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Vested Stock Options Exercised-
Proceeds From Early Exercise Of Stock Options-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents186.20
Payments Of Deferred Stock Issuance Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities4.51
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow26.68
Total Cash Flow20.39
4 historic quarters locked

Sign in to unlock the full Tarsus Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Tarsus Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001819790-26-000064

Figures are derived from filed reports and may be restated. Historical data is subject to revision.